Daiichi Sankyo has been ordered to pay an 8% royalty rate on sales of its breast cancer therapy Enhertu by a Texas court, on top of an earlier award of $41.8 million in damages, in an ongoing ...

Daiichi Sankyo exited Ranbaxy in 2013 and said the Singhs should have used their 34% stake in Fortis to pay for the arbitration award, but these shares had been lost as the lenders invoked the ...

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the U.S. regulatory finish line. The FDA has greenlighted the drug ...